Exicure Inc XCUR:NASDAQ

Set AlertOptionsStreaming Charts
Last Price$2.22NASDAQ Closing Price as of 4:00PM ET 1/26/21
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change-0.07(3.06%)
Bid (Size)$2.21 (3)
Ask (Size)$2.27 (20)
Day Low / High$2.20 - 2.33
Volume582.3 K
Sell
Buy
Chart Style Historical Chart Icon Download historical data
 

View Miscellaneous Commercial Services IndustryPeer Comparison as of 01/26/2021

Timeframe
 

Exicure Inc ( NASDAQ )

Price: $2.22
Change: -0.07 (3.06%)
Volume: 582.3 K
4:00PM ET 1/26/2021
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

Universal Technical Institute Inc ( NYSE )

Price: $6.20
Change: -0.04 (0.64%)
Volume: 87.6 K
7:00PM ET 1/26/2021
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

Cinedigm Corp ( NASDAQ )

Price: $1.35
Change: -0.07 (4.93%)
Volume: 16.3 M
6:43PM ET 1/26/2021
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

Gaia Inc ( NASDAQ )

Price: $9.60
Change: -0.08 (0.83%)
Volume: 49.8 K
4:00PM ET 1/26/2021
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

GP Strategies Corp ( NYSE )

Price: $12.43
Change: -0.19 (1.51%)
Volume: 37.9 K
7:00PM ET 1/26/2021
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain

Read more news Recent News

Exicure Secures Two Fast Track Designations for Cavrotolimod From FDA; Stock Climbs
10:34AM ET 1/11/2021 MT Newswires

Exicure (XCUR) said on Monday the US Food and Drug Administration has granted Fast Track designations for its product candidate, cavrotolimod, for the...

Exicure Files for Up to $150 Million Mixed Shelf
3:23AM ET 12/22/2020 MT Newswires

Exicure (XCUR) on Monday filed a registration statement covering the potential sale of up to $150 million in securities. The securities, which may be...

Exicure Obtains Two US Patents, Patent Allowance for Mechanics Behind Anti-Tumor Agent Cavrotolimod
11:27AM ET 12/21/2020 MT Newswires

Exicure (XCUR) said Monday that it has received two US patents as well as patent allowance covering cavrotolimod, which is being developed as a potential...

--Analyst Actions: BMO Capital Starts Exicure at Outperform With $6 Price Target
8:29AM ET 12/18/2020 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

View all Commentary and Analysis

Exicure (XCUR) Investor Presentation - Slideshow
8:14PM ET 11/17/2020 Seeking Alpha

Wall Street Breakfast: The Week Ahead
6:41AM ET 9/13/2020 Seeking Alpha

Stocks To Watch: Apple, Snowflake, Pfizer And Moderna In Focus
8:40AM ET 9/12/2020 Seeking Alpha

Wall Street Breakfast: The Week Ahead
7:40AM ET 8/30/2020 Seeking Alpha

Company Profile

Business DescriptionExicure, Inc. is a clinical-stage biotechnology company, which engages in the discovery, research, and development of treatments based on spherical nucleic acid technology (SNA). It focuses on neurology, immuno-oncology, inflammatory diseases, and other genetic disorders. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL. View company web site for more details
Address2430 North Halsted Street
Chicago, Illinois 60614
Phone+1.847.673.1700
Number of EmployeesN/A
Recent SEC Filing01/11/20218-K
CEO, CFO, Secretary & DirectorDavid A. Giljohann
Chief Operating OfficerMatthias Schroff
Chief Medical OfficerDouglas E. Feltner

Company Highlights

Price Open$2.33
Previous Close$2.29
52 Week Range$0.96 - 3.30
Market Capitalization$194.5 M
Shares Outstanding87.6 M
SectorCommercial Services
IndustryMiscellaneous Commercial Services
Next Earnings Announcement03/09/2021

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.27
Beta vs. S&P 500N/A
Revenue$118.0 K
Net Profit Margin-130.87%
Return on Equity-27.37%

Analyst Ratings as of 12/17/2020

Buy
5
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset